普洛药业
(000739)
| 流通市值：189.68亿 | | | 总市值：189.75亿 |
| 流通股本：11.58亿 | | | 总股本：11.58亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,444,486,087.31 | 2,730,189,121.97 | 12,021,863,029.21 | 9,290,220,207.76 |
| 营业收入 | 5,444,486,087.31 | 2,730,189,121.97 | 12,021,863,029.21 | 9,290,220,207.76 |
| 二、营业总成本 | 4,838,162,638.1 | 2,490,659,565.28 | 10,858,989,886.75 | 8,295,069,270.45 |
| 营业成本 | 4,043,570,318.77 | 2,074,526,168.27 | 9,155,202,967.93 | 7,039,196,715.18 |
| 税金及附加 | 27,536,402.53 | 11,560,775.82 | 56,309,811.43 | 38,464,108.76 |
| 销售费用 | 259,713,136.71 | 135,739,283.33 | 640,232,098.94 | 399,845,866 |
| 管理费用 | 204,260,092.13 | 107,741,561.05 | 480,940,845.39 | 364,405,634.04 |
| 研发费用 | 324,198,969.9 | 169,688,023.08 | 641,471,760.73 | 467,201,967.23 |
| 财务费用 | -21,116,281.94 | -8,596,246.27 | -115,167,597.67 | -14,045,020.76 |
| 其中:利息费用 | 10,350,464.49 | 4,679,152.24 | 28,581,876.49 | 22,658,655.71 |
| 其中:利息收入 | 26,348,057.71 | 12,730,989.19 | 92,174,157.39 | 61,734,298.32 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -42,550.68 | - | 7,965,391.23 | 8,469,505.02 |
| 加:投资收益 | 35,840,695.16 | 39,456,689.06 | -18,092,847.19 | -8,133,805.36 |
| 资产处置收益 | 1,159,599.1 | 207,218.06 | 279,470.84 | 940,320.95 |
| 资产减值损失(新) | -28,683,809.33 | -17,834,633.53 | -70,224,534.92 | -64,057,956.27 |
| 信用减值损失(新) | 5,063,458.78 | 7,678,573.87 | 921,524.36 | 4,482,243.72 |
| 其他收益 | 40,588,542.69 | 29,399,795.97 | 128,348,756.48 | 86,271,219.6 |
| 四、营业利润 | 660,249,384.93 | 298,437,200.12 | 1,212,070,903.26 | 1,023,122,464.97 |
| 加:营业外收入 | 924,100.75 | 530,079.37 | 1,643,305.98 | 1,534,043.08 |
| 减:营业外支出 | 2,585,687.31 | 1,495,996.55 | 10,423,836.23 | 4,812,177.38 |
| 五、利润总额 | 658,587,798.37 | 297,471,282.94 | 1,203,290,373.01 | 1,019,844,330.67 |
| 减:所得税费用 | 95,516,386.28 | 48,895,021.36 | 172,443,650.71 | 150,456,206.83 |
| 六、净利润 | 563,071,412.09 | 248,576,261.58 | 1,030,846,722.3 | 869,388,123.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 563,071,412.09 | 248,576,261.58 | 1,030,846,722.3 | 869,388,123.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 563,047,273.19 | 248,547,145.11 | 1,031,121,698.55 | 869,652,417.71 |
| 少数股东损益 | 24,138.9 | 29,116.47 | -274,976.25 | -264,293.87 |
| 扣除非经常损益后的净利润 | 520,545,789.49 | 205,665,722.98 | 984,439,126.95 | 831,092,074.08 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.49 | 0.21 | 0.89 | 0.75 |
| (二)稀释每股收益 | 0.49 | 0.21 | 0.89 | 0.75 |
| 八、其他综合收益 | 318,525.63 | 91,753.66 | 10,713,506.8 | 3,571,372.34 |
| 归属于母公司股东的其他综合收益 | 318,525.63 | 91,753.66 | 10,713,506.8 | 3,571,372.34 |
| 九、综合收益总额 | 563,389,937.72 | 248,668,015.24 | 1,041,560,229.1 | 872,959,496.18 |
| 归属于母公司股东的综合收益总额 | 563,365,798.82 | 248,638,898.77 | 1,041,835,205.35 | 873,223,790.05 |
| 归属于少数股东的综合收益总额 | 24,138.9 | 29,116.47 | -274,976.25 | -264,293.87 |
| 公告日期 | 2025-08-20 | 2025-04-18 | 2025-03-11 | 2024-10-18 |
| 审计意见(境内) | | | 标准无保留意见 | |